Sanofi-Aventis to market seasonal flu vaccine in China

By Tan Ee Lyn

HONG KONG (Reuters) - French drugmaker Sanofi-Aventis hopes to sell 25 million doses of seasonal flu vaccine annually into China’s largely untapped domestic market once its plant in the southern city of Shenzhen goes onstream in 2012.

Wayne Pisano, head of the company’s vaccines arm Sanofi-Pasteur, said on Monday only two percent of Chinese were vaccinated against seasonal flu each year, a fraction of the coverage in Europe and the United States.

“Immunization is between 20 and 40 percent in Europe and North America, but only 2 percent in China … by producing the vaccine in China with this new facility, we are going to increase our capacity immediately with an additional 25 million doses and it will allow us to expand that and double it as the needs in China grow,” Pisano told reporters in Hong Kong.

The 70 million euros ($95 million) plant will use China-made antigen, substances in vaccine that stimulate production of antibodies in the human body. It is cultured using chicken eggs.

Asked how the company will ensure quality given China’s problematic food safety records, Pisano said: “We have a single quality standard and so the facility in Shenzhen, the quality of the product will be identical to our vaccines produced in France and the U.S.”

“We’ve identified almost 50 farms that can provide eggs for production and (will) narrow down to two that can meet the quality standards that we set for manufacturing.”

“We work with the farmers to make sure that they can meet the requirements,” Pisano said.



Related Posts:

BEIJING/HONGKONG (Reuters) - A 19-year-old woman has died of the H5N1 bird flu virus in Beijing after coming into contact with poultry, health authorities in Beijing and Hong Kong said on Tuesday. This human H5N1 case would be China’s first in almost a year. Experts said while the case was not unexpected as the virus is

Full Post: China confirms woman died of bird flu in Beijing

By Will Dunham WASHINGTON (Reuters) - U.S. health officials asked doctors on Thursday to be alert for possible cases of meningitis and other illnesses in children caused by Hib bacteria amid an ongoing vaccine shortage. Officials are most concerned about bacterial meningitis and sepsis, a bloodstream infection, caused by Hib (Haemophilus influenzae type b) in children under

Full Post: Doctors to be on guard for meningitis in kids

By Laura MacInnis GENEVA (Reuters) - Governments need to overcome their “pandemic fatigue” and act quickly to finalize a response plan to potential flu threats, leading drugmakers said on Thursday. The pharmaceutical industry is “very close to ready” to respond to a potential outbreak by shifting seasonal flu vaccine production to more targeted pandemic ones, said Stephen

Full Post: Vaccine makers urge speedy accord on pandemic plan

BEIJING (Reuters) - China, battling to restore trust in its products amid a tainted milk scandal, has closed a local pharmaceutical company whose herbal injections have been linked to the deaths of three people. China last month expanded a product recall for Wandashan Pharmaceutical, a company based in northeastern Heilongjiang province, after the injections caused adverse

Full Post: China closes herbal drug firm linked to deaths

By Tan Ee Lyn HONG KONG (Reuters) - Hong Kong will soon begin testing meat, vegetables and processed food for melamine, a move that underlines concerns about environmental contamination and food safety, experts say. Thousands of children in China fell sick with kidney problems in recent months after consuming milk that had been mixed with the plastic-making

Full Post: Hong Kong to test meat, vegetables for melamine

Site Navigation

Most Read


Most Read